| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
149,189 |
138,429 |
$6.33M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
54,994 |
54,156 |
$4.25M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
33,540 |
33,249 |
$2.04M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
70,273 |
64,707 |
$1.88M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
55,742 |
50,461 |
$1.83M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
40,762 |
38,374 |
$1.01M |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
19,434 |
18,401 |
$334K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
15,280 |
14,052 |
$248K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
17,000 |
14,526 |
$240K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
5,072 |
4,903 |
$195K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
7,043 |
6,862 |
$166K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
6,245 |
5,548 |
$126K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
17,937 |
17,676 |
$122K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
8,291 |
7,177 |
$95K |
| 99354 |
|
1,576 |
973 |
$87K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
7,335 |
6,525 |
$76K |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
2,157 |
1,198 |
$61K |
| 87428 |
|
989 |
964 |
$59K |
| 93000 |
|
2,081 |
2,054 |
$57K |
| 81003 |
|
26,968 |
25,844 |
$49K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,980 |
1,933 |
$43K |
| 69209 |
|
3,319 |
3,250 |
$34K |
| 87807 |
|
3,065 |
3,016 |
$25K |
| 99215 |
Prolong outpt/office vis |
357 |
356 |
$21K |
| 81025 |
|
6,962 |
6,822 |
$21K |
| 29515 |
|
373 |
362 |
$19K |
| A7016 |
Dome and mouthpiece, used with small volume ultrasonic nebulizer |
3,514 |
2,559 |
$19K |
| 90714 |
|
646 |
634 |
$18K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
333 |
321 |
$16K |
| 29125 |
|
254 |
246 |
$13K |
| 29280 |
|
274 |
263 |
$9K |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
947 |
926 |
$9K |
| 94760 |
|
2,711 |
2,630 |
$7K |
| 29530 |
|
210 |
193 |
$5K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
573 |
550 |
$5K |
| A6449 |
Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard |
1,533 |
1,484 |
$5K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
588 |
578 |
$5K |
| 81002 |
|
2,071 |
2,020 |
$5K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
437 |
430 |
$4K |
| 69210 |
|
141 |
138 |
$4K |
| 10060 |
|
101 |
94 |
$4K |
| 82947 |
|
1,425 |
1,386 |
$4K |
| 85018 |
|
2,125 |
2,060 |
$4K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
208 |
197 |
$4K |
| 29260 |
|
121 |
120 |
$4K |
| 29540 |
|
254 |
242 |
$4K |
| S0077 |
Injection, clindamycin phosphate, 300 mg |
262 |
237 |
$3K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
399 |
362 |
$3K |
| 99051 |
|
9,417 |
8,866 |
$3K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
290 |
277 |
$2K |
| 86308 |
|
383 |
379 |
$2K |
| 12001 |
|
24 |
24 |
$2K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
14 |
14 |
$1K |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
7,932 |
6,789 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
34 |
34 |
$1K |
| 11730 |
|
30 |
30 |
$897.52 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
318 |
316 |
$883.99 |
| 99072 |
|
4,801 |
4,448 |
$801.25 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
150 |
135 |
$756.92 |
| 99000 |
|
220 |
217 |
$711.87 |
| 29130 |
|
25 |
24 |
$615.72 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
19 |
19 |
$505.26 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
15 |
15 |
$392.98 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
151 |
126 |
$199.40 |
| J3490 |
Unclassified drugs |
13 |
13 |
$60.00 |